Introduction
Interleukin-18 (IL-18) is a pleiotropic member of the IL-1 cytokine family, which was originally described as IFNginducing factor. 1 Synergistically with IL-12, IL-18 exhibits a strong Th1-promoting activity. 2, 3 Production of this proinflammatory cytokine induces IFNg, TNFa and IL-1b secretion and enhances cytotoxic activity of NK cells. [4] [5] [6] A broad range of immuno-regulatory cells, including activated macrophages and dendritic cells but also stromal like cells such as keratinocytes, and osteoblasts, can produce IL-18. [7] [8] [9] Similar to IL-1, IL-18 is present in cells as a precursor protein, which has to be cleaved to an 18-kDa mature glycoprotein by IL-1b converting enzyme (ICE, caspase-1). Initiation of intracellular signalling by secreted IL-18 starts with the formation of a high-affinity receptor complex, comprising out of the IL-18 binding areceptor chain (IL-18Ra) and the b-chain (IL-18Rb), which itself cannot bind IL-18.
10,11 Dimerization of both receptor units upon IL-18 binding results in activation of intracellular signal transduction pathways induced by recruitment of the adapter protein MyD88 towards the receptor complex, followed by binding of interleukin receptor activated kinase (IRAK) and TNF receptor associated factor-6 (TRAF-6). The formation of this activation complex of the IL-18 signal cascade finally leads to downstream NFkB-mediated activation of transcription. 2 Recently, a novel physiological inhibitor of IL-18 signalling has been discovered. This inhibitor, called IL-18 binding protein (IL-18BP) is a protein with the ability to bind and neutralize IL-18.
12 IL-18BP is a nonmembrane bound protein, which has only a single Ig domain and shows little resemblance with the IL-1 receptor family. Elevated levels of IL-18BP are found in serum of patients suffering from septic shock and IL-18BP is expressed in response to IFNg. 13 Several isoforms have been discovered resulting from alternative mRNA splicing of which IL-18BPa and IL-18BPc exhibit the highest affinity towards IL-18.
14 These isoforms are able to neutralize 495% of the biological activity of IL-18 at a 1:1 molar ratio. The immune modulating role of IL-18BP is furthermore underlined by reports of the presence of viral forms of IL-18BP, which have been located in DNA of poxvirus family. 15 As a proinflammatory cytokine, IL-18 has been associated with the development of several inflammatory diseases including RA. 6 IL-18 is highly expressed in RA synovium and correlates with inflammation. 16 Significantly elevated concentrations are found in both serum 17 and synovial fluid of RA patients, 18, 19 and can be rapidly reduced by anti-TNFa treatment. 20 Furthermore, the influential role of IL-18 in experimental arthritis was obtained from studies with IL-18 À/À mice, which showed impaired development of collagen-induced arthritis (CIA). 21 The importance of IL-18 in experimental arthritis was furthermore shown in the acute streptococcal cell wall (SCW) arthritis animal model. Systemic blockage of endogenous IL-18 through neutralizing antibodies significantly reduced joint inflammation probably by reduction of local TNFa and IL-1b levels. 22 Systemic treatment of CIA with recombinant human IL-18BP showed amelioration of arthritis. 23 However, IL-18 is involved in both innate and acquired immunity during host defence against foreign pathogens and systemic neutralization could lead to severe impairment of the immune response. 24 Therefore, in some situations it appears preferable to choose local instead of systemic treatment. Studies by Bakker et al 25, 26 already showed functionality of local intra-articular therapy for arthritis using IL-1 receptor antagonist.
The aim of this present study is to develop a therapeutic approach to treat arthritis through local neutralization of IL-18. To this end we constructed an adenoviral vector containing the murine IL-18BP isoform c gene. Local treatment with IL-18BP was achieved through intra-articular (i.a.) injection of the adenoviral vector before clinical manifestation of the CIA. Here we report that IL-18 is a pivotal cytokine during onset of CIA, and that local intra-articular treatment with an adenoviral vector containing the IL-18BPc gene is a novel approach to modulate experimental arthritis.
Results

Validation of adenoviral IL-18BPc vector
To test the functionality of the adenoviral vector, NIH 3T3 fibroblasts were transfected with AdCMVIL-18BPc. Transfected NIH 3T3 fibroblasts showed clear intracellular expression of mIL-18BPc, which was not observed in nontransfected or AdCMVLuciferase control-transfected cells (Figure 1 ). Conditioned culture supernatants of transfected cells were collected 30 h post-transfection. Precipitation of secreted proteins of transfected cells, followed by immunoblotting revealed a sharp band at 40 kDa, indicating the production of secreted IL-18BPc by transfected cells (Figure 1c, lane 3) . Normal or control transfected cells did not constitutively produce IL-18BPc ( Figure 1c , lanes 1 and 2).
Adenoviral overexpressed IL-18BPc neutralizes IL-18 activity in vitro
To determine the biologic activity of secreted mIL18BPc, conditioned culture supernatants were tested on (Figure 1d ).
Effect of neutralization of IL-18 through IL-18BPc on local cytokine levels Inhibition of IL-18 through IL-18BPc was tested in the acute SCW arthritis model. At 2 days prior to i.a. challenge with SCW, the synovial lining was transfected with AdCMVIL-18BPc or the control AdCMVLuciferase vector. Transfection of the synovial lining with IL-18BPc resulted in a significant inhibition of TNFa production at 90 min after intra-articular SCW challenge. Levels of IFNg in supernatants of SCW challenged patellae resulted in marked but not significant reduction of IFNg production at 24 h after SCW challenge ( Table 1) .
Overexpression of IL-18BPc results in decreased severity of CIA To elucidate the local role of IL-18 in the onset of CIA, knee joints of immunized DBA/1 mice were injected with 1 Â 10 7 PFU AdCMVIL-18BPc, before clinical manifestation of the disease. Macroscopic evaluation of dissected knee joints showed a clear reduction of joint swelling by viral IL-18BPc treatment (Figure 2a) . Further histological examination showed that IL-18BPc overexpression reduced influx of polymorphonuclear cells and hypertrophy of the synovial lining as illustrated by a decrease in synovial thickening (Figure 2b) . Furthermore, histological scoring of proteoglycan depletion of the cartilage matrix, cartilage erosion and bone erosion in the treated knee joints showed that intra-articular overexpression of IL-18BPc protected the joint significantly against these parameters of arthritic pathology ( Figure 3 ).
Intra-articular overexpression of IL-18BPc in the knee joint reduces incidence and severity in distal paws Development of the experimental arthritis was followed in the paws after injection of the adenoviral vector at day 21 till time of sacrifice at day 27. Overexpression of IL18BPc in both knee joints had a distal protective effect on the CIA development in the draining paws. At day 27, only 25% of the paws in IL-18BPc-treated animals developed signs of arthritis, while in control-treated animals 72% of the paws were affected (Figure 4a ). Figure 4b shows the average clinical score in the affected paws during time course of the CIA. Treatment with IL18BPc significantly ameliorated the CIA severity in the affected paws from day 24. Although IL-18BPc treatment compared to control treatment reduced severity in the affected paws, IL-18BPc was not able to fully arrest progression of the disease in some animals.
IL-18BPc reduces serum levels of IL-6
As a marker of disease activity, IL-6 levels were determined at the time of sacrifice in serum of IL18BPc-and control-treated animals. High levels of IL-6 (27807245 pg/ml) could be detected in serum of control-treated animals, while serum levels of IL-6 were significantly reduced in IL-18BPc-treated mice (9937162 pg/ml) ( Figure 5 ).
Effect of IL-18BPc on serum levels of anticollagen type II Abs
As a result of the involvement of IL-18 in T-cell polarization towards a Th1 subset and the relation between IgG isotypes balance, and Th1/Th2 balance, we determined collagen type II specific IgG titers in sera at time of sacrifice. As shown in Figure 6 , intra-articular treatment with IL-18BPc had no effect on circulating levels of collagen II specific IgG1 levels, while it reduced collagen II specific circulating IgG2a Abs levels.
Discussion
This study was performed to develop and determine the efficacy of local IL-18BPc gene therapy in CIA. Several recent studies have reported the importance of IL-18 in experimental arthritis 21 and described possible therapeutic potential of IL-18 neutralization. 22, 23 In the later papers the effect of systemic neutralization has been reported through application of an IL-18 neutralizing antibody strategy or injection of large amounts of recombinant IL-18BP. This present study is the first study to report efficient i.a. intervention with IL-18 signalling in CIA through application of recombinant adenoviruses containing the murine form of the IL18BPc.
To achieve local expression of the inhibitor, we chose for an adenoviral expression system in which the construct was under the control of the cytomegalo virus (CMV) promoter. In vitro testing of the newly constructed adenoviral vector on transfection efficacy and expression by fibroblasts showed high intracellular levels and secretion of the IL-18BPc. Furthermore, supernatants of AdCMVIL-18BPc transfected cells showed high IL-18 neutralizing activity, thus proving secretion of a biologically active inhibitor of IL-18. From these in vitro experiments, we estimated that the IL-18 neutralizing capacity of the i.a. injected AdCMVIL-18BPc (10 7 PFU) is about 5 ng IL-18 at a 1:1 stoichiometry (see Figure 1d) , theoretically leading to a concentration of 500 ng mIL18BPc per millilitre synovial fluid in the murine joint. It is technically not possible to measure the amount of mIL18BPc produced, but we expect that the level will be far above the level of IL-18 found in synovial fluid of RA patients. 19 To test the in vivo functionality of AdCMVIL18BPc we used the acute SCW challenge arthritis model. IL-18 has been shown to be involved in acute SCW challenge and the cytokine is able to induce several cytokines in different subsets of cells, including TNFa and IFNg from macrophages and T cells. 22, 27, 28 Evaluation of direct effects of IL-18 neutralization by adenoviral-induced expression of IL-18BP during acute SCW inflammation revealed reduced levels of locally produced TNFa in washouts of synovial tissue. After validation of IL-18 neutralization through the IL-18BPc virus, these results clearly show the direct involvement of IL-18 as a proinflammatory cytokine during the early phase of an arthritic process.
The observed proinflammatory profile of IL-18 was first described in studies by Gracie et al 18 and Wei et al, 21 in which they demonstrated the pivotal role of IL-18 in the development of inflammatory arthritis. Other studies by Joosten et al 22, 23 verified the importance of IL-18 in experimental arthritis through systemic neutralization of IL-18. Besides this systemic role of IL-18, it has been demonstrated that IL-18 is also produced in high amounts by the synovial lining of RA patients. 16, 18 As a result of these high levels of IL-18 in local inflammatory processes intra-articular neutralization of IL-18 by adenoviral overexpressed IL-18BPc during onset of CIA could be effective. While control-treated mice developed a progressive inflammatory articular disease, Exogenous IL-18BPc ameliorates CIA RL Smeets et al intra-articular overexpression of IL-18BPc before clinical manifestation of the CIA resulted in amelioration of the arthritis. Clinical effects of IL-18BPc treatment were observed as markedly lower incidence and reduced severity of erosive joint destruction of the CIA in dissected knee joints.
Interestingly, an additional effect on the poly-arthritic CIA model was observed. Intra-articular treatment of the knee joints also reduced the severity of the CIA in the distal paws of IL-18BPc-treated animals. Observation of this protection of adjacent joints opens new prospects for local treatment of experimental arthritis. Similar observations have been made after intra-articular treatment of CIA with IL-1 receptor antagonist, which also results in amelioration of the CIA in the distal paws of treated mice. 25, 26 Whether these effects are the result of a direct local inhibition of cytokine spillover and antigen release by reduced inflammation or caused by leakage of IL18BPc to distal joints remains to be established. When comparing incidence versus severity in the distal paws of IL-18BP-treated animals, IL-18 significantly reduced incidence while increase in severity of affected hind paws could not be halted. This observation suggests an important role for IL-18 in the onset of arthritis, while its role in progression of disease remains unclear.
IL-18 is considered to be a pivotal cytokine regarding T-cell activation, resulting in production of IFNg and polarization of Th1 responses. Impressive synergy of IL-18 on IFNg production by T cells can be observed in the presence of IL-12. 3, 29, 30 In animal studies CIA mice injected with IL-12 alone, developed earlier onset and more severe progression of the arthritis. 31 A resembling synergy between IL-12 and IL-18 was observed through co-injection of these cytokines in CIA mice, which enhanced incidence and disease severity above those of IL-12 alone. 31 Results from our study show that local inhibition of IL-18 results in a significant lower incidence and severity of the arthritis. However, increase in severity of affected hind paws could not be halted. As a result of the resemblance in function between IL-18 and IL-12, this IL-18-independent progression of severity could be the resultant of IL-12 function. Therefore, therapeutic strategies should be developed to locally block both IL-18 and IL-12, which could prove to be effective in the future.
Wei et al 21 also showed that induction of CIA in IL-18 KO mice had no effect on IgG1 titres directed towards collagen type II, but showed significant reduction in Figure 4 Reduced disease severity in distal paws through intra-articular overexpression of IL-18BPc. Treatment with IL-18BPc reduced incidence (a) and severity (b) of CIA in mice compared to the control treatment. DBA/1 mice with CIA were treated through i.a. injection of 10 7 PFU AdCMVIL-18BPc or the control vector after receiving the booster at day 21 as described in Materials and methods. Incidence was calculated as cumulative incidence of positive distal paws (clinical score40.25 was considered positive). Difference between incidence curves was determined by w 2 -contingency analysis. CIA was scored by two observers in a blinded manner. CIA severity in animals is presented as mean clinical scores of affected hind paws and analysed with the Mann-Whitney U-test. *, Po0.05 in treated versus control group. Data are means7s.e.m. (n¼11). Figure 5 Reduced levels of IL-6 in sera of IL-18BPc treated animals. Levels of the acute phase marker IL-6 were determined in sera of mice, sacrificed at day 27 after immunization. Differences between IL-6 levels of IL-18BPc-treated animals (n¼11) and control-treated animals (n¼10) were determined using the Mann-Whitney U-test. *, Po0.01 in treated versus control. Data are presented as individual serum measurements; mean absorbances indicated per group. IgG2a titres. This reduction in IgG2a Abs, which is normally produced during Th1-mediated responses, underlines the involvement of IL-18 in induction of polarization towards a Th1-mediated CIA. Interestingly, after local treatment of experimental arthritis we also observed no differences in serum titres of IgG1 Abs directed towards collagen type II between control-and IL-18BPc-treated animals, while IgG2a Abs showed a marked but, due to large variation, not significant reduction. These data suggest possible influence of locally produced IL-18 in modulation of the systemic Th1 response. We also found a systemic reduction of circulating levels of IL-6 after local treatment with IL-18BPc. From the same study by Wei et al 21 similar reduction in circulating levels of IL-6 was observed in sera obtained at 37 days after induction of CIA in IL-18 KO mice compared to wild-type DBA/1 mice. As a result of the effects of local treatment with IL-18BPc on the described systemic parameters IL-6 and IgG2a Abs, a possible mechanism could be that the observed systemic effects of local IL-18 neutralization depend on reduced release of IL-18 and other cytokines from inflamed joints.
In recent years, several systemic cytokine-inhibiting therapies in RA have been introduced of which the antiTNFa treatment is the best studied. However, it has become clear that systemic inhibition of TNFa can induce some adverse effects. These effects can vary from mild opportunistic diseases to tuberculosis or even multiple sclerosis. [32] [33] [34] Although the effective treatment of RA through anti-TNFa therapy, it appears from these studies that deprivation of this cytokine in some cases can result in severe impairment of the immune response. It is not unthinkable that systemic cytokine blocking therapies will eventually result in systemic impairment of innate and acquired immunity, while local therapies can be less interfering with systemic processes. Since systemic IL-18BP treatment can also result in scavenging of IL-18, ultimately leading to deprivation, it is warranted to develop local treatments that can minimize interference on a systemic level. As a result of the involvement of IL-18 in pathogenesis of other inflammatory diseases like type I diabetes mellitus, 6 local expression in affected organs of IL-18BPc may be the way to go.
The rapid induction of IL-18 during inflammatory processes and its proinflammatory character make IL-18 a logical target in many inflammatory disorders. With this study, we have confirmed the local proinflammatory role of IL-18 in experimental arthritis. More interestingly, we now present a novel and local gene therapeutic approach that neutralizes endogenous IL-18, which may provide a future joint protective therapy in RA.
Materials and methods
Animals
Male 10-to 12-week-old DBA-1/bom mice obtained from Bomholdgärd (Ry, Denmark). C57/Bl6 mice were bred and housed in top-filter cages at the animal facility. Mice injected with adenoviral vectors during experiments were housed in low-pressure isolator cages. The animals were fed a standard diet with water and food adlibitum. All in vivo studies complied with national legislation and were approved by local authorities of the Care and Use of Animals with related codes of practice.
Construction of IL-18BPc adenoviral vector
The first step in construction of a first generation E1/E3 deleted serotype-5 adenovirus was the cloning of the gene of interest. IL-18BPc was copied from isolated murine liver cDNA, using a nested primer strategy. The 5 0 inner primer was modified to contain XhoI restriction site at the 5 0 end. The 3 0 inner primer contained a XbaI site in the 3 0 end. Recombinant virus was produced according to the method described by Vogelstein et al. 35 Briefly, a single-banded PCR product was obtained and subsequently digested with XhoI and XbaI before ligation into the pShuttle (Stratagene) containing the CMV promoter. Homologous recombination of AdEasy-1 viral back-bone with the pShuttleCMV containing the IL18BPc construct was performed in BJ 5183 bacteria after electroporation (BIOrad gene pulser). Positive clones were selected and recombinant viral vector plasmid was amplified using JM109 bacteria. Purified recombinant adenoviral vector DNA was linearized through digestion with PacI and transfected into 911 viral packaging cells using Lipofectamin 2000 (Invitrogen, Carlsbad, CA, USA). Viruses were purified using 2 Â CsCl gradient purification and stored in small aliquots at À801C. Replication deficiency of the virus was determined by PCR and tested on HeLa cells.
Construction of IL-18 responsive NFkB reporter cell line
The IL-18 responsive murine thymoma derived T-cell line EL-4D6/76 was used for construction of an IL-18-sensitive reporter cell line. Briefly, a promoter containing a 5xNFkB binding site cloned upstream of the Luciferase gene was extracted from the pGl3b reporter vector, which was a kind gift from Prof. Dr W Falk (Department of Internal Medicine, University of Regensburg, Germany). The obtained NFkB reporter construct was ligated into a promoterless eukaryotic expression vector pcDNA3.1A (Invitrogen, Carlsbad, CA, USA). Cells were transfected cells using Lipofectamin2000 (Invitrogen, Carlsbad, CA, USA) and selected on stable integration with neomycin-G418
Detection of mIL-18BPc through immunocytochemistry
To test virus functionality, 2x10 5 NIH 3T3 fibroblasts were seeded and transfected for 2 h under serum-free culture conditions with different MOIs of AdCMVIL18BPc or the control vector. Following transfection, cells were washed and cultured for 30 h in DMEM containing 10% FCS and antibiotics. Conditioned supernatants were used for in IL-18 inhibition assay (See IL-18 bioassay). For intracellular detection of IL-18BPc, cells were fixed with À201C methanol for 15 min, followed by 15 min incubation in phosphate-buffered saline (PBS) containing 0.1% Triton X-100. After fixation, cells were incubated for 1 h at room temperature with PBS containing mouse IL18BPc-specific polyclonal goat IgG (R&D systems Europe, Abingdon, UK). Cells were washed five times with PBS and incubated for 1 h with the second HRP conjugated Ab. Intracellular expressed IL-18BPc was detected using DAB staining reaction.
Detection of mIL-18BPc by immunoblotting
Cell-free 30-h conditioned supernatants of mIL-18BPc transfected cells, luciferase transfected or nontransfected Exogenous IL-18BPc ameliorates CIA RL Smeets et al controls were precipitated using trichloroacetic acid (TCA). Briefly, an equal volume of 20% TCA was added to the supernatant. After 30-min incubation at 01C, samples were centrifuged for 15 min at 41C (13 000 Â g). Pellets were washed in 5% TCA, followed by centrifugation. Finally the obtained pellet was washed with acetone and resuspended in protein sample buffer. TCA precipitated proteins were separated using 10% SDS-PAGE. After blotting IL-18BPc was detected using mouse IL-18BPc-specific polyclonal goat IgG (R&D systems Europe, Abingdon, UK).
IL-18 bio-assay
The effect of adenoviral overexpression of mIL-18BPc on IL-18 was tested using IL-18 responsive EL-4D6/76 NFkB reporter cells. Reporter cells (2-4 Â 10 4 ) were incubated for 24 h in the presence of conditioned supernatants containing IL-18BPc or control supernatants of transfected cells. IL-18 induced production of luciferase was quantified using Bright-Glo luciferase assay system (Promega, Madison, WI, USA) followed by luminometric detection according to the manufacturer's protocol (Polarstar Galaxy, BMG, Offenburg, Germany).
Induction of CIA
Bovine collagen type II was dissolved in 0.05 M acetic acid to a concentration of 2 mg/ml and was emulsified in equal volumes of CFA (2 mg/ml of M. tuberculosis strain H37Ra; Difco Laboratories, Detroid, MI, USA). The mice were immunized intra dermal at the base of the tail with 100 ml of emulsion (100 mg of bovine collagen type II). On day 21, mice were given an i.p. booster injection of 100 mg of collagen type II dissolved in PBS. The mice without clinical manifestation of arthritis were selected and i.a. injected with 10 7 PFU AdCMVIL-18BPc or the control adenoviral vector (ADCMVLuc) into both knees. Normally first signs of arthritis onset occur around days 22-24, in particular in the ankles. Periarticular arthritic development of the hind paw and ankle joint was macroscopically monitored till day 27, at which the experiment was terminated and the mice were scarified. During this period clinical severity of the arthritis was scored by two independent observers in a blinded manner on a scale ranging from 0 to 2 for each limb. Cumulative scoring depending on redness, swelling and in later stadium ankylosis was as follows; 0 -no changes; 0.25 -1 to 2 toes red or swollen; 0.5 -3 to 5 toes red or swollen; 0.5 -swollen ankle; 0.5 -swollen footpad; 0.5 -severe swelling and ankylosis. At day 27 the experiment was terminated and the mice were bled. Knees were dissected and scored for macroscopical swelling on a scale ranging from 0 to 2.
SCW preparation and induction of SCW arthritis
Streptococcus pyogenes T12 organisms were cultured overnight in Todd-Hewitt broth. Cell walls were prepared as described previously. 36 The resulting 10 000 Â g supernatant was used in experiments and contained 11% muramic acid. Before induction of SCW arthritis mice were intra-articularly injected with 10 7 PFU AdCMVIL18BPc or the control AdLuc virus. At 1 day after transfection of the synovial lining, acute bilateral arthritis was induced by i.a. injection of 25 mg of SCW (Rhamnose content) dissolved in 5 ml of PBS into the knee joints of C57Bl/6 mice.
Histology
Whole dissected knee joints were fixed in phosphate buffered 4% paraformaldehyde, followed by decalcification with 5% formic acid and embedded in paraffin wax. Serial tissue sections of 7 mm were stained with safranin-O or heamatoxylin/eosin (HE) prior to microscopical analysis. Loss of bone and noncalcified cartilage, which is characteristic for CIA, was scored on a 0-3 scale ranging from no effects to complete loss of bone structure or noncalcified cartilage layer. The degree of proteoglycan (PG) depletion was determined by measurement of glycosaminoglycan content of the noncalcified cartilage layer, which was scored in safranin-O-stained sections also on a scale from 0 to 3 ranging from no depletion to severe depletion. These histopathological changes were scored in blinded manner by two observers. Synovial thickening was quantified using computer analysed microscopic measurement (Leica Qwin; Leica, germany).
Determination of specific IgG-titres against collagen type II IgG1, IgG2a and total IgG anticollagen Abs titres against bovine CII were determined through ELISA. Briefly, 96-well plates were coated with 10-mg of bovine CII, followed by blockage of nonspecific binding sites. Serial dilutions of the mouse sera were added, followed by incubation with isotype-specific goat anti-mouse peroxidase (Southern Biotechnology Associates, Birmingham, AL, USA) and substrate (5-aminosalicylic acid; Sigma). Plates were read at 492 nm.
Measurement of IL-6 serum levels
Concentrations of IL-6 in serum were determined using the B9 bioassay as described before. 37 Briefly, serial dilutions of serum samples were made in culture medium in order to quantify IL-6 levels. B9 cells (5 Â 10 3 ) were added to serum sample dilutions and incubated for 3 days (371C-5%CO 2 ). At 4 h before harvesting the cells, 0.25 mCi of 3H-thymidine was added. The amount of incorporated 3H-thymidine was quantified using a Micro Beta-plate reader (Perkin-Elmer, The Netherlands).
Determination of IFNg and TNFa
Concentrations of IFNg and TNFa were determined in patellae washouts. Patellae were isolated from the knee, leaving adjacent synovial tissue surrounding the patellae. Patellae were cultured in RPMI 1640 medium at room temperature for 1 h (200 ml/patella). IFNg was determined using ELISA (Organon Technica NV, Boxtel, The Netherlands). TNFa levels were determined by nonequilibrium radioimmunoassay (RIA). 38 Detection limits for IFNg was 730 pg/ml and 40 pg/ml for TNFa.
Statistical analysis
Significance of differences was determined using Student's t-test or Mann-Whitney U-test (GraphPad Prism, San Diego CA, USA). P-values of 0.05 or less were regarded as significant.
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